Focus: Dyne Therapeutics is a publicly traded biotech focused on antibody-oligonucleotide conjugate treatments for rare neuromuscular diseases, with a ~300-person workforce based in Waltham, MA.
Profile data last refreshed 8h ago · AI intelligence enriched 1mo ago
Hot — 78 jobs added in 30d
Net +63 (78 new, 15 removed). Aggressive expansion phase.
Strong fit for risk-tolerant professionals seeking early-stage upside in validated rare-disease platform with clear upcoming binary catalysts.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Dyne Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Dyne Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Form 4 Dyne Therapeutics Inc For: 8 July By Investing.com - Investing.com Canada
Form 4 Dyne Therapeutics Inc For: 8 July By Investing.com Investing.com Canada
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
[144] Dyne Therapeutics, Inc. SEC Filing Stock Titan
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? - The Motley Fool
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? The Motley Fool
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? - The Globe and Mail
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? The Globe and Mail
DYN Stock Price | Analyst Target 42.43 & Strong Buy Consensus - eToro
DYN Stock Price | Analyst Target 42.43 & Strong Buy Consensus eToro
Price to book forward of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView
Price to book forward of Dyne Therapeutics, Inc. – NASDAQ:DYN TradingView
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo